Neuiropeptide Y (NPY) is one of the most abundant peptide transmitters in the mammalian brain. In the periphery it is costored and coreleased with norepinephrine from sympathetic nerve terminals. However, the physiological functions of this peptide remain unclear because of the absence of specific high-affinity receptor antagonists. Three potent NPY receptor antagonists were synthesized and tested for their biological activity in in vitro, ex vivo, and in vivo functional assays. We describe here the effects of these antagonists inhibiting specific radiolabeled NPY binding at Y1 and Y2 receptors and antagonizing the effects of NPY in human erythroleukmia cell intracellular calcium mobilization, perfusion pressure in the isolated rat kidney, and mean arterial blood pressure in anesthetized rats.
widely distributed throughout the central and peripheral nervous systems (2) (3) (4) . On the basis of the pharmacological effects observed in experimental animals after central or peripheral administration of NPY, the peptide has tentatively been implicated in the regulation of a wide variety of biological functions such as vascular tone, feeding behavior, mood, and hormone secretion among others (for a review see ref. 5) . At least two NPY receptor subtypes have been described based on the relative affinity of different NPY agonists: NPY-Y1 receptors require essentially the full NPY sequence of amino acids (see Fig. 1 ) for activation and have high affinity for the analog [Leu31,Pro34]NPY, whereas NPY-Y2 receptors can be activated by NPY and the shorter C-terminal fragment, NPY13-36, but have low affinity for [Leu31,Pro34]NPY (6, 7) . A third subtype (NPY-Y3) that recognizes all three of the above peptides but is insensitive to the NPY homolog, peptide YY, has been proposed (8, 9) . Direct demonstration of a physiological and pathophysiological role for NPY has been hampered by the lack of specific, high-affinity NPY receptor antagonists. Receptor antagonists based on modified Cterminal fragments of NPY (10) and analogs of the nonpeptide benextramine (11, 12) have been reported. However, these compounds have relatively weak receptor affinity and thus are of limited value. Of potential interest is the recent report by Balasubramaniam et al. (13) describing the antagonistic activity of [DTrp32]NPY in a feeding behavior model. This manuscript reports on peptidergic high-affinity NPY receptor antagonists and their potent inhibitory action on the effects of the peptide in several in vitro and in vivo functional assays.
MATERIALS AND METHODS
Human erythroleukemia (HEL) and SK-N-MC cells were obtained from American Type Culture Collection. Cell culture medium, Eagle's minimal essential medium (EMEM) and RPMI 1640 medium, were obtained from GIBCO, bovine calf serum was from HyClone, L-glutamine solution was from JRH Biosciences (Lenexa, KS), and fura-2 acetoxymethyl ester was from Molecular Probes. All other reagents were of the highest purity available.
[3H]Propionyl NPY (specific activity 70 Ci/ mmol; 1 Ci = 37 GBq) and 1251-NPY (specific activity, 2000 Ci/mmol) were purchased from Amersham. Unlabeled porcine NPY was obtained from D. Klapper (University of North Carolina, Chapel Hill) and further purified in-house as described (14) .
Peptide Synthesis. Peptides were synthesized by the solidphase method. Compound 2 was obtained by oxidation of the reduced monomer and purification of the dimer by HPLC. Compound 3 was synthesized by using standard solid-phase synthesis. Compound 4 was synthesized by coupling BOC-Lglutamic acid fluorenylmethyl ester and a-Boc 3-FmOC-Ldiamino propionic acid in position 8 and 6, respectively. Dimerization was achieved on the resin by treatment with piperidine followed by a coupling reagent. Detailed synthesis is described in the compounds' patent publication (15 
RESULTS
We have recently reported (16) on the structure and activity of a nonapeptide (see compound 1, Fig. 1 ) displaying high affinity for rat brain receptors (IC50 = 180 nM) and potent antagonistic activity (IC50 = 10 nM) in the NPY-Y1 receptormediated intracellular calcium increase in HEL cells. In an attempt to improve on the potency of the above antagonist, we synthesized dimeric analogs of 1 using either disulfide bridges, diamino pimelic acid, or lactam bridges (Fig. 1, compounds 2 , 3, and 4, respectively). Table 1 shows the activity of these compounds, compared to that of NPY and NPY analogs, displacing specifically bound [3H]NPY from rat brain membranes or 125I-NPY from SK-N-MC neuroblastoma cells. The three dimeric structures show significantly higher affinities than compound 1 for Y2 (rat brain) and Y1 (SK-N-MC cells) receptors; thus, these dimers are potent, albeit apparently nonselective, NPY receptor ligands. Even though our compounds do not appear to be selective for a particular NPY receptor subtype, their apparent affinity for many other neurotransmitter or peptide receptors is several orders of magnitude weaker than for NPY receptors (see Table 2 ).
Next, we examined the ability of these compounds to inhibit the NPY-induced increase in cytosolic calcium in HEL cells. We have previously shown that HEL cells mobilize intracel- (14, 18) . Fig. 2 Left shows the effect of a 0.5 nM dose of each compound, added to HEL cells in suspension, 30 sec prior to the stimulation with a halfmaximal concentration of NPY (5 nM). It can be observed that, at this concentration, the three compounds inhibit very effectively (40-80%) the increase in cytosolic calcium induced by NPY. Fig. 2 Inset shows the IC50 for the compounds calculated from the dose-response curves for the inhibition of the calcium response to 5 nM NPY for each of the antagonists. None of the compounds has agonistic activity, as no increase in cytosolic calcium is observed in response to their addition to the cell suspension prior to NPY (even up to 1 ,uM), indicating that these compounds would behave as pure antagonists at the NPY receptor expressed in HEL cells. The shows a higher antagonistic potency in this system as well. Supporting the specificity of our compounds for NPY receptors, increases in kidney perfusion pressure induced by methoxamine (at agonist), isoproterenol (,B agonist), or depolarization with KCI are not affected by the presence of these antagonists (results not shown).
NPY has been shown to be a potent vasoconstrictor in vivo, elevating arterial blood pressure in rats (reviewed in ref. 19 ). Fig. 4 shows the in vivo NPY receptor blocking effect of compound 4, which exhibits the greatest potency in all of the above assays. i.v. infusion of compound 4 into anesthetized Sprague-Dawley rats dose dependently inhibits the pressor response produced by a bolus i.v. injection of an ED50 dose of NPY (1 nmol/kg). This antagonism is selective for the NPY receptors since the pressor response induced by a bolus i.v. injection of norepinephrine (3 nmol/kg) is not altered.
DISCUSSION
Initial hypotheses regarding the physiological role(s) for NPY have been based on the in vivo pharmacological effects observed after exogenous administration of the peptide. Wahlestedt et al. (20) have recently provided convincing evidence that NPY may be involved in the mechanism of anxiety, circumventing the lack of specific NPY receptor antagonists by using an antisense oligonucleotide to the rat Y1 receptor. In addition, intrahypothalamic administration of monoclonal antibodies to NPY produces a marked reduction in food intake in the fasted rat (21, 22) , suggesting a physiological role for NPY in the control of feeding behavior after a period of food deprivation. However, in order to ascribe a true physiological function to a neuropeptide we must ultimately rely on the changes observed after neutralizing the effect of the endogenously released peptide with potent and specific receptor antagonists. The compounds described here, particularly 1229U91 (compound 4), represent a first generation of high-affinity NPY antagonists that will help unveil the participation of NPY in important physiological functions and in the development of therapeutic agents to treat central as well as peripheral pathologies associated with an NPYergic transmission hyperactivity. While this manuscript was in preparation, Rudolf et al. (24) reported on a nonpeptide NPY antagonist apparently selective for the NPY-Y1 type of receptor.
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